Cystic Fibrosis

What is Cystic Fibrosis?

Cystic fibrosis (CF) is a life-threatening genetic disorder that primarily affects the respiratory and digestive systems. The condition is caused by mutations in the CFTR gene, which produces thick, sticky mucus that clogs the lungs and pancreas, leading to serious infections and digestive problems. CF affects approximately 70,000 people worldwide, with the highest prevalence among individuals of Northern European descent. Early diagnosis and comprehensive treatment have significantly improved life expectancy, with many patients now living into their 40s and beyond.

Key statistics

Symptoms

Common symptoms include persistent cough with thick mucus, recurrent lung infections, salty-tasting skin, poor weight gain, and bulky, greasy stools.

Respiratory symptoms typically appear first and include a chronic cough that produces thick, sticky mucus, frequent chest infections, wheezing, shortness of breath, and inflamed nasal passages or stuffy nose. Digestive symptoms include poor weight gain despite good appetite, bulky and greasy stools, severe constipation, and intestinal blockage in newborns (meconium ileus). Other signs may include very salty-tasting skin, clubbing of fingers and toes, and in males, infertility due to absence of the vas deferens. Serious complications include pneumothorax (collapsed lung), massive hemoptysis (coughing up blood), respiratory failure, diabetes, liver disease, and osteoporosis.

Causes and risk factors

Cystic fibrosis is caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene located on chromosome 7. This gene provides instructions for making a protein that regulates the movement of salt and water in and out of cells. When the CFTR protein is defective or missing, thick, sticky mucus builds up in the lungs, pancreas, and other organs. The most common mutation, F508del, accounts for approximately 70% of CF cases worldwide, though more than 2,000 different mutations have been identified. CF follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutated copy of the gene for a child to develop the condition. Risk factors include having parents who are both carriers of CFTR mutations, with the highest risk in populations of Northern European, Ashkenazi Jewish, and certain Mediterranean ancestries.

Submit Your Paper

Prevention

Currently, there is no known way to prevent cystic fibrosis. However, early detection through genetic screening and carrier testing can help families make informed decisions. Carrier screening is recommended for couples planning pregnancy, particularly those of high-risk ethnic backgrounds. Prenatal testing through amniocentesis or chorionic villus sampling can detect CF in a developing fetus when both parents are known carriers. Newborn screening programs in many countries can identify CF within the first few weeks of life, allowing for early intervention that significantly improves outcomes.

Complications

Without proper treatment, cystic fibrosis leads to progressive lung damage, respiratory failure, and death typically in childhood or young adulthood. Respiratory complications include chronic infections with bacteria such as Pseudomonas aeruginosa, bronchiectasis (permanent widening of airways), pulmonary hypertension, and cor pulmonale (heart failure due to lung disease). Digestive complications include pancreatic insufficiency leading to malnutrition, CF-related diabetes mellitus, liver cirrhosis, gallstones, and distal intestinal obstruction syndrome. Other complications may include osteoporosis due to malabsorption, kidney stones, arthritis, depression, and anxiety. Male infertility affects over 95% of men with CF due to congenital bilateral absence of the vas deferens.

Diagnosis

Diagnosis typically begins with newborn screening using immunoreactive trypsinogen (IRT) levels, followed by genetic testing for CFTR mutations if elevated. The gold standard confirmatory test is the sweat chloride test, which measures salt levels in sweat; values above 60 mmol/L are diagnostic for CF. Additional diagnostic tests include comprehensive CFTR gene sequencing, nasal potential difference testing, and intestinal current measurement. Prenatal diagnosis can be performed through amniocentesis or chorionic villus sampling when both parents are known carriers. Clinical criteria supporting diagnosis include chronic respiratory symptoms, pancreatic insufficiency, failure to thrive, and family history of CF.

Treatment

Treatment for cystic fibrosis requires a comprehensive, multidisciplinary approach focusing on clearing mucus from the lungs, preventing and treating infections, and maintaining nutrition. Airway clearance techniques include chest physiotherapy, high-frequency chest wall oscillation devices, and inhaled medications such as hypertonic saline and dornase alfa to thin mucus. CFTR modulators represent a major breakthrough, with ivacaftor, lumacaftor, tezacaftor, and elexacaftor targeting specific genetic mutations to restore CFTR protein function. Antibiotic therapy includes inhaled tobramycin and aztreonam for chronic Pseudomonas infections, with oral or intravenous antibiotics for acute exacerbations. Pancreatic enzyme replacement therapy with pancrelipase is essential for most patients to aid digestion and nutrition. Lung transplantation may be considered for end-stage disease, with five-year survival rates exceeding 60%.

Prognosis

The prognosis for cystic fibrosis has dramatically improved over recent decades due to advances in treatment and care. The median predicted survival age has increased from the mid-teens in the 1980s to approximately 44 years today in developed countries with comprehensive CF care programs. Factors associated with better outcomes include early diagnosis through newborn screening, access to specialized CF care centers, good nutritional status, and newer therapies like CFTR modulators. The introduction of highly effective CFTR modulator combinations like elexacaftor-tezacaftor-ivacaftor has shown remarkable improvements in lung function, nutritional status, and quality of life for patients with eligible mutations. However, prognosis varies significantly based on genotype, access to care, socioeconomic factors, and adherence to treatment regimens.

Quality of life

Living with cystic fibrosis requires significant daily management but many patients lead fulfilling lives with proper care and support. Treatment regimens typically require 2-4 hours daily, including airway clearance techniques, inhaled medications, and enzyme supplementation with meals. A high-calorie, high-fat diet with vitamin supplementation is essential, often requiring 120-150% of normal caloric intake. Regular exercise is strongly encouraged as it helps clear mucus, improves cardiovascular fitness, and enhances quality of life; activities like swimming, cycling, and team sports are particularly beneficial. Mental health support is crucial, as rates of depression and anxiety are higher in CF patients; counseling, support groups, and sometimes medication may be helpful. Educational and workplace accommodations may include flexible schedules for treatments, access to private spaces for airway clearance, and infection control measures. Many adults with CF successfully pursue higher education, careers, and relationships with appropriate planning and support.

Pregnancy and fertility

Women with cystic fibrosis can have successful pregnancies, though fertility may be reduced due to thick cervical mucus and nutritional factors. Preconception counseling is essential to optimize lung function, nutritional status, and medication regimens. During pregnancy, increased caloric needs, more frequent monitoring of lung function, and careful antibiotic selection are important considerations. Some CF medications require adjustment or discontinuation during pregnancy and breastfeeding. Male fertility is significantly affected, with over 95% of men having congenital bilateral absence of the vas deferens, though sperm production is usually normal; assisted reproductive techniques like ICSI can help achieve pregnancy. Genetic counseling is recommended for all CF patients considering parenthood, as each child has a 50% chance of being a carrier if the partner is not a carrier, or higher risks if the partner is also a carrier.

Children

Cystic fibrosis typically presents in early infancy, often detected through newborn screening programs. In children, failure to thrive despite good appetite is common, along with recurrent respiratory infections, chronic cough, and bulky stools. Growth and development require careful monitoring, with aggressive nutritional support including high-calorie foods, pancreatic enzymes, and fat-soluble vitamins. School accommodations may include time for treatments, access to snacks and enzymes, infection control measures during illness outbreaks, and modified physical education when appropriate. Transition planning to adult care typically begins in adolescence, focusing on developing independence in treatment management, understanding reproductive health implications, and preparing for adult healthcare systems. Psychosocial support is particularly important during adolescence when treatment adherence may decline and body image concerns emerge.

When to see a doctor

Immediate medical attention is required for signs of pulmonary exacerbation including increased cough, changes in mucus color or volume, fever, decreased appetite, weight loss, or increased fatigue. Emergency care is needed for hemoptysis (coughing up blood), severe shortness of breath, chest pain suggesting pneumothorax, or signs of diabetic ketoacidosis in patients with CF-related diabetes. Routine CF care requires regular follow-up every 3-4 months at specialized centers, with more frequent visits during illness or treatment changes. Parents should contact healthcare providers for persistent respiratory symptoms in children, feeding difficulties, poor weight gain, or unusually salty-tasting skin. Annual comprehensive evaluations should include pulmonary function tests, imaging, nutritional assessment, and screening for complications like diabetes and osteoporosis.

Regional context

Cystic fibrosis prevalence varies significantly among populations in the Caucasus region, with lower frequencies reported compared to Northern European populations. Limited data suggests reduced prevalence in Georgia, Armenia, and Azerbaijan, though comprehensive population studies are lacking. Access to specialized CF care, including CFTR modulators and advanced treatments, may be limited in some areas of the region. GMJ welcomes contributions from regional researchers to build the evidence base for cystic fibrosis in the Caucasus, particularly regarding local mutation patterns, carrier frequencies, and treatment outcomes.

Research and clinical trials

Current research focuses on developing new CFTR modulators for rare mutations, gene therapy approaches, and anti-inflammatory treatments. Promising areas include mRNA therapy to restore CFTR protein production, bacteriophage therapy for resistant infections, and stem cell research for tissue repair. Clinical trials are investigating combination therapies to maximize CFTR function and novel approaches to address the inflammatory cascade in CF lungs. Researchers are also exploring personalized medicine approaches based on individual mutation profiles and developing better treatments for CF-related complications like diabetes and liver disease. Patients can find current clinical trials through ClinicalTrials.gov, and many CF care centers participate in research studies offering access to experimental treatments.

Frequently asked questions

Is cystic fibrosis contagious?

No, cystic fibrosis is a genetic condition and cannot be transmitted from person to person. However, people with CF are at risk for catching infections from others, particularly respiratory infections.

Can people with CF live normal lifespans?

While CF significantly affects life expectancy, many people now live into their 40s and beyond with proper treatment. New therapies like CFTR modulators are dramatically improving outcomes and may further extend lifespans.

What is the difference between being a carrier and having CF?

Carriers have one mutated copy of the CFTR gene but don’t develop CF symptoms. People with CF have two mutated copies, one inherited from each parent.

Can CF be cured?

Currently, there is no cure for CF, but treatments can effectively manage symptoms and slow disease progression. Gene therapy and other emerging treatments offer hope for potential cures in the future.

How does CF affect daily life?

CF requires significant daily management including medications, airway clearance, and nutritional support, typically taking 2-4 hours per day. However, many people with CF attend school, work, travel, and participate in normal activities with proper planning.

Support and resources

Key organizations providing support and information include the Cystic Fibrosis Foundation (cff.org), CF Trust in the UK (cysticfibrosis.org.uk), and Cystic Fibrosis Worldwide (cfww.org). Orphanet (orpha.net) provides comprehensive information about rare diseases including CF. The European Cystic Fibrosis Society (ecfs.eu) offers resources for patients and healthcare providers across Europe. EURORDIS (eurordis.org) advocates for rare disease patients and families throughout Europe. Local and national CF organizations in many countries provide patient support, advocacy, and funding for research and care programs.

Related conditions

Primary ciliary dyskinesia causes similar respiratory symptoms due to defective cilia function. Bronchiectasis involves permanent airway dilation and can occur in CF or as a separate condition. Pancreatic insufficiency may occur in CF or other pancreatic disorders. Chronic sinusitis is common in CF patients due to thick mucus in nasal passages. CFTR-related disorders include milder conditions caused by CFTR mutations such as congenital bilateral absence of vas deferens.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.